Nikolas London Details Cross-Sectional Analysis of anti-VEGF Drugs

Nikolas London, MD, of Retina Consultants San Diego sat down with MD Magazine at the ARVO 2017 meeting in Baltimore, Maryland, to discuss the findings of a cross-sectional analysis his team was presenting. The project looked at a series of major trials on aflibercept and ranibizumab used in patients with branch and central retinal vein occlusion.

London details the nuances of the findings in this video, and the major takeaways: “The bottom line is that all patients seem to do quite well treated with anti-VEGF therapy, regardless of the agent used,” London concluded.